Opioid Use in Early Pregnancy Not Tied to Most Birth Defects
FRIDAY, Feb. 12, 2021 -- Opioid use in early pregnancy is associated with a small increase in risk for cleft palate but no increase in risk for most major congenital malformations, and macrolide use in pregnancy is not associated with increased risk for major birth defects in offspring, according to two studies published online Feb. 10 in The BMJ.
Brian T. Bateman, M.D., from Brigham and Women's Hospital in Boston, and colleagues examined the risks of first trimester exposure to prescription opioids for major congenital malformations. Data were included for 1,602,580 publicly insured (MAX) and 1,177,676 commercially insured (MarketScan) pregnant women, of whom 4.4 and 1.1 percent, respectively, had two or more dispensations of any opioid during the first trimester. The researchers found that the absolute risk of malformations was 41.0 versus 32.0 per 1,000 pregnancies exposed to opioids versus unexposed in the MAX cohort and 42.6 versus 37.3 per 1,000 in the MarketScan cohort. The pooled unadjusted relative risk estimates were increased for all outcomes, but were attenuated after adjustment (relative risk for malformations overall: 1.06; 95 percent confidence interval, 1.02 to 1.10).
Nicholas Worm Andersson, M.D., from the University Hospital Bispebjerg and Frederiksberg in Copenhagen, Denmark, and colleagues examined the association between macrolide antibiotic use in pregnancy (13,019 pregnancies) and major birth defects. The researchers found that there were 35.1 infants born with major birth defects per 1,000 pregnancies among women who had used macrolides during pregnancy, compared with 37.0 per 1,000 pregnancies among women who had used penicillin (relative risk ratio, 0.95; 95 percent confidence interval, 0.84 to 1.08).
"We believe that our data provide reassurance about the risk of major birth defects when treatment with macrolide antibiotics is needed during pregnancy," Andersson and colleagues write.
Several authors from the Bateman study disclosed financial ties to the pharmaceutical industry.
© 2021 HealthDay. All rights reserved.
Posted: February 2021
Read this next
THURSDAY, Feb. 25, 2021 -- Low disease activity and remission are feasible goals for women with rheumatoid arthritis (RA) cared for with a modern treatment approach during...
THURSDAY, Feb. 25, 2021 -- The total lifetime opioid-related costs generated by symptomatic knee osteoarthritis (SKOA) in the United States are $14.0 billion, about half of which...
TUESDAY, Feb. 23, 2021 -- Children conceived by assisted reproduction technology (ART) are shorter and lighter at birth than those conceived naturally, but have similar height and...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.